News

Appeal Court rules that NICE procedure was unfair

BMJ 2008; 336 doi: 10.1136/bmj.39574.351782.DB (Published 8 May 2008)
Cite this as: BMJ 2008;336:1035.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Clare Dyer
  1. 1BMJ

    The hopes of people with mild Alzheimer’s disease of having access to acetylcholinesterase inhibitors through the NHS were boosted last week when three appeal court judges ruled that a key step in the process for appraising the drugs for NHS use was “procedurally unfair.”

    The court unanimously overturned a High Court ruling that the National Institute for Health and Clinical Excellence (NICE) acted fairly when it refused to supply the drug company Eisai with a full version of the computer model it used to decide that the treatment would not be cost effective for the early stages of the illness (BMJ 2007;335:319; doi: 10.1136/bmj.39307.630347.DB).

    The drugs cost £2.50 (€3.17; …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular